Relay Therapeutics Inc 's ROA from the second quarter of 2026 to the second quarter of 2025 and 5 Year Period

Return on Assets, Quarterly Results, Trends, Rankings, Statistics

What is Relay Therapeutics Inc 's ROA in the second quarter of 2026?
Relay Therapeutics Inc recorded a cumulative net loss of $-286 million during 12 months ending in the second quarter of 2026, resulting in a negative return on assets (ROA) of -38.67%.

However, within the Healthcare sector 474 other companies had a higher return on assets. While Return on assets, overall ranking has advanced in the Jun 30 2026 quarter, so far to 3788, from total ROA ranking in the first quarter of 2026 at 4438.

What is ROA?

Select the Comparisons :

None ▼

Select the Ratio:

Return on Assets ROA▼

None ▼

Return on Assets ROA▼

Download as CSV

Commercial Data Licensing & OEM

Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms

API & Data Feeds

Programmatic access to normalized fundamentals & ratios.

Return On Assets	(Jun 30 2026) II. Quarter	(Mar 31 2026) I. Quarter	(Dec 31 2025) IV. Quarter	(Sep 30 2025) III. Quarter	(Jun 30 2025) II. Quarter
Y / Y Total Assets Change	32.74 %	-12.48 %	-23.99 %	-23.4 %	1.95 %
Y / Y Net Income Change	-	-	-	-	-
Net Income (TTM) in million	-286	-273	-276	-298	-312
Return On Assets (TTM)	-38.67 %	-40.11 %	-39.22 %	-39.47 %	-38.7 %
RLAY's Total Ranking	# 3788	# 4438	# 3886	# 3905	# 4015
Total Assets (TTM) in million	967	700	621	670	729
Seq. Total Assets Change	38.28 %	12.6 %	-7.26 %	-8.07 %	-8.82 %
Seq. Net Income Change	-	-	-	-	-

RLAY's 5 Years Annual ROA >> Back to RLAY Management Effectiveness >> Compare RLAY ROA to its Competitors

Return On Assets Company Ranking
Within:	No.
Industry	# 56
Sector	# 475
Overall	# 3738

Return On Assets Statistics
High	Average	Low
-28.41 %	-37.76 %	-54.55 %
(Dec 31 2022)		(Jun 30 2021)

News about Relay Therapeutics Inc Return on Assets ROA

Promising Interim Data on RLY-2608 A Breakthrough in Progression-Free Survival by Relay Therapeutics

In a pivotal moment for precision oncology, Relay Therapeutics Inc. (NASDAQ: RLAY) has announced encouraging interim data from its ongoing trial of RLY-2608, a targeted therapy designed for patients with advanced solid tumors. The findings signal a potential step forward in the quest for more effective cancer treatments, particularly in terms of improving progression-free survival (PFS) in a population that often faces limited options.Progression-free survival, a crucial endpoint in oncology trials, measures the length of time during and after treatment a patient lives without the disease worsening. The positive interim results for RLY-2608 demonstrate not only a favorable safety profile but also promising indications that patients may experience an extended period of stability in their disease course.

Upcoming Webcast by Relay Therapeutics Insights into RLY-2608 Data on September 9, 2024

: Relay Therapeutics has announced a webcast slated for September 9, 2024, during which the company will share crucial data regarding its investigational drug RLY-2608. This article examines the significance of this upcoming event within the context of drug development, particularly in precision medicine and oncology. Relay Therapeutics, a biotechnology company at the forefront of innovative therapies, is poised to reveal key findings related to RLY-2608, a molecule developed for treating cancers driven by specific genetic mutations. The company’s recent announcement of a webcast scheduled for September 9, 2024, is a pivotal moment for stakeholders in the pharmaceutical and biotechnology landscape, as it promises to elucidate the therapeutic potential and clinical applicability of RLY-2608.

Financial Statements
Relay Therapeutics Inc 's Assets	$ 967 million	RLAY's Balance sheet
Relay Therapeutics Inc 's Income	$ -84 million	Quarterly RLAY's Income Statement
RLAY's Income by Division		See RLAY's Income by Division

Annual Return On Assets	(Dec 31 2025) FY 2025	(Dec 31 2024) FY 2024	(Dec 31 2023) FY 2023	(Dec 31 2022) FY 2022	(Dec 31 2021) FY 2021
Y / Y Total Assets Change	-29.04 %	4.35 %	-24.2 %	4.91 %	26.89 %
Total Assets in million	580	817	783	1,033	985
Y / Y Net Income Change	-	-	-	-	-
Net Income in million	-276	-338	-342	-291	-364
Annual Return On Assets	-47.67 %	-41.31 %	-43.66 %	-28.11 %	-36.94 %

RLAY's 5 Years Annual ROA >> Back to RLAY Management Effectiveness >> Compare RLAY ROA to its Competitors

More Return On Assets Ratios
RLAY's' Return on Assets at Yahoo Finance
Biotechnology & Pharmaceuticals Industry Return On Assets Trends and Statistics
Healthcare Sector Roa Statistics
Roa Trends for overall market
RLAY's Roa Ratio versus Biotechnology & Pharmaceuticals Industry, Healthcare Sector and overall Market
Highest Ranking Return On Assets
Lowest Ranking Return On Assets
Subscribers only: Roa for RLAY's Competitors
Subscribers only: Roa for Relay Therapeutics Inc 's Suppliers
Subscribers only: Return On Assets for RLAY's Customers

You may also want to know
RLAY's Roi	RLAY's Inventory Turnover Ratio	RLAY's Growth Rates	RLAY's Dividend Comparisons
	RLAY's Profitability Ratios	RLAY's Asset Turnover Ratio	RLAY's Dividend Growth
RLAY's Roe	RLAY's Valuation Ratios	RLAY's Financial Strength Ratios	RLAY's Dividend Payout Ratio

Companies with similar Return On Assets at Jun 30 2026, within Healthcare Sector

ROA

Date modified: 2026-09-08T01:24:38+00:00

Help

About us

Products

Data downloads

API

CSIMarket Company, Sector, Industry, Market Analysis, Stock Quotes, Earnings, Economy, News and Research.

Intraday data delayed per exchange requirements. All quotes are in local exchange time. Intraday data delayed 15 minutes for Nasdaq, and other exchanges. Fundamental and financial data for Stocks, Sector, Industry, and Economic Indicators provided by CSIMarket.com

Disclaimer: Information provided by CSIMarket.com is for informational purposes only and does not constitute investment advice, recommendation, or solicitation to buy or sell any security.